Press release
Prostate Cancer Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies
"Prostate Cancer Pipeline Insight, 2023" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Prostate Cancer Market.
The Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Prostate Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the emerging therapies for the treatment of Prostate Cancer and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Prostate Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn more about the major developments in the therapeutics domain:
https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Prostate Cancer Therapeutic Segment @
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Prostate Cancer Therapeutics Landscape
There are approx. 200+ key companies developing therapies for Prostate Cancer. Currently, Merck & Co is leading the therapeutics market with its Prostate Cancer drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Prostate Cancer Therapeutics Market Include:
Advantagene, Advaxis, Inc., Allife Medical Science and Technology, Amgen, Arvinas Inc, Astellas Pharma, AstraZeneca, Bavarian Nordic, Bayer, BeiGene, Blue Earth Diagnostics, Bracco Diagnostics, Inc, Bristol-Myers Squibb, Cancer Targeted Technology, Cardiff Oncology, Clarity Pharmaceuticals, Clovis Oncology, eFFECTOR Therapeutics, Eli Lilly and Company, Emtora Biosciences, Epizyme, ESSA Pharma, Exelixis, Fortis Therapeutics, Inc., Genmab, Genovax, Harpoon Therapeutics, Hinova Pharmaceuticals, Hoffmann-La Roche, Immunomedics, Innocrin Pharmaceutical, Janssen Research & Development, Jiangsu Hengrui Medicine Co., Laekna Limited, Leap Therapeutics, Luye Pharma Group, MacroGenics, Matrix Biomed, Merck & Co, Myovant Sciences/Takeda, Novartis, Nymox Pharmaceutical, Orion Corporation, Pfizer, Plexxikon, Regeneron Pharmaceuticals, RhoVac, Sanofi, Sophiris Bio, Suzhou Kintor Pharmaceutical, Tavanta Therapeutics, Teneobio, Inc., Tracon, Trovagene, Vaccitech, Veru Inc., Zenith Epigenetics, and others.
Prostate Cancer Emerging and Marketed Drugs Covered in the Report:
• 177Lu-PSMA-617: NovartisXtandi (Enzalutamide): Astellas Pharma/Pfizer
• EPI-7386: ESSA Pharma
• Erleada (apalutamide): Janssen Pharmaceutical
• Ipatasertib (RG7440): Hoffmann-La Roche
• Keytruda: Merck Sharp & Dohme
• Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme
• Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation
• ODM-208: Orion
• Pembrolizumab: Merck & Co
• ProstAtak: Advantagene
• Rubraca (Rucaparib): Clovis Oncology
• Talzoparib: Pfizer/Astellas Pharma
• ZEN 3694: Zenith Epigenetics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Prostate Cancer Current Treatment Patterns
4. Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Prostate Cancer Late Stage Products (Phase-III)
7. Prostate Cancer Mid-Stage Products (Phase-II)
8. Prostate Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prostate Cancer Discontinued Products
13. Prostate Cancer Product Profiles
14. Key Companies in the Prostate Cancer Market
15. Key Products in the Prostate Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Prostate Cancer Unmet Needs
18. Prostate Cancer Future Perspectives
19. Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prostate Cancer Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies here
News-ID: 3008601 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
